Hjem › Tripelnegativ brystkreft › Texas › Dallas
Kliniske studier for Tripelnegativ brystkreft i Dallas, TX
18 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Dallas (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- UT Southwestern, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Dallas
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- Texas Oncology - DFW ( Site 8007), Dallas
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
- Texas Oncology - DFW ( Site 8000), Dallas
- Parkland Health & Hospital System ( Site 0096), Dallas
- University of Texas Southwestern Medical Center ( Site 0032), Dallas
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- University of Texas Southwestern Medical Center, Dallas
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekruttererFase 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- og 2 flere
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Texas Oncology, P.A., Dallas
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- Baylor University Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Baylor University Medical Center, Dallas
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
RekruttererFase 1/2
- Texas Oncology - DFW, Dallas
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekruttererFase 1
- Dren Investigational Site, Dallas
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
RekruttererTidlig fase 1
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
RekruttererFase 1
- NEXT Oncology, Dallas, Dallas
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
- Grand Rapids, MI15 studier
Andre studier i Dallas
- Brystkreft55 studier
- Ikke-småcellet lungekreft52 studier
- Metastatisk kreft42 studier
- Hjertesvikt42 studier
- Kreft (alle typer)37 studier
- Prostatakreft36 studier
- Kolorektal kreft33 studier
- Fedme30 studier
- Eggstokkreft28 studier
- Lungekreft27 studier
- Blærekreft27 studier
- Endometriekreft24 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.